HER2-Negative Breast Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00733408Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerTreatment